Markets move fast. You should move faster. Be the first to know when deals break, stocks move, or biotech headlines hit. Sign up to get breaking news alerts the moment they happen.
Exicure shares positive Phase 2 data on burixafor (GPC-100) showing reliable and rapid stem cell mobilization for autologous transplant in multiple myeloma patients, even those with prior challenging therapies.
Terns Pharmaceuticals (TERN) announces encouraging Phase 1 results for TERN-701, showing 64% response rates in relapsed/refractory chronic myeloid leukemia patients with favorable safety profile.
Google is developing two categories of AI-powered smart glasses—one with displays and one audio-focused—set to compete with Meta, Snap, and Apple in 2026.
A U.S. judge ruled that Google must limit default search and AI app contracts with Apple, Samsung, and other device makers to one year, opening the door for more competition in search and generative AI.
Nurix Therapeutics presented positive Phase 1 data for its BTK degrader, bexobrutideg (NX-5948), showing high response rates and favorable safety in heavily pre-treated Waldenström Macroglobulinemia patients.
Wave Life Sciences' WVE-007 demonstrates 9.4% visceral fat reduction with muscle preservation in Phase 1 trial, earning positive analyst ratings and buy recommendations.
